

J Andrew Livingston

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3035603/publications.pdf>

Version: 2024-02-01

48
papers

1,060
citations

516710

16
h-index

454955

30
g-index

49
all docs

49
docs citations

49
times ranked

1784
citing authors

#	ARTICLE	IF	CITATIONS
1	Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 66-97.	4.9	206
2	Immuno-genomic landscape of osteosarcoma. Nature Communications, 2020, 11, 1008.	12.8	143
3	Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clinical Sarcoma Research, 2017, 7, 11.	2.3	61
4	Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Scientific Reports, 2017, 7, 11836.	3.3	57
5	Chemotherapy for Bone Sarcoma in Adults. Journal of Oncology Practice, 2016, 12, 208-216.	2.5	44
6	3D tissue-engineered model of Ewing's sarcoma. Advanced Drug Delivery Reviews, 2014, 79-80, 155-171.	13.7	39
7	Long-term survival among 5-year survivors of adolescent and young adult cancer. Cancer, 2020, 126, 3708-3718.	4.1	33
8	Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. Cell Reports, 2021, 34, 108678.	6.4	33
9	Genomics and the Immune Landscape of Osteosarcoma. Advances in Experimental Medicine and Biology, 2020, 1258, 21-36.	1.6	31
10	Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. Current Oncology Reports, 2018, 20, 37.	4.0	27
11	Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association. Nature Communications, 2022, 13, 42.	12.8	27
12	Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist, 2017, 22, 1271-1277.	3.7	20
13	MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers, 2019, 11, 677.	3.7	20
14	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers, 2020, 12, 1768.	3.7	20
15	Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. Cancers, 2019, 11, 1283.	3.7	19
16	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget, 2016, 7, 64421-64430.	1.8	17
17	PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma, 2020, 2020, 1-6.	1.3	16
18	Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma. Pediatric Blood and Cancer, 2017, 64, e26318.	1.5	15

#	ARTICLE	IF	CITATIONS
19	Impact of Race, Ethnicity, and Socioeconomic Status over Time on the Long-term Survival of Adolescent and Young Adult Hodgkin Lymphoma Survivors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1717-1725.	2.5	15
20	Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy. <i>Oncotarget</i> , 2018, 9, 1602-1616.	1.8	15
21	Disparities in Adolescent and Young Adult Sarcoma Survival: Analyses of the Texas Cancer Registry and the National SEER Data. <i>Journal of Adolescent and Young Adult Oncology</i> , 2018, 7, 681-687.	1.3	14
22	The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. <i>Nature Communications</i> , 2022, 13, .	12.8	14
23	Chemotherapy for Bone Sarcomas in Adults: The MD Anderson Experience. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e656-e660.	3.8	13
24	Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1315-1323.	4.1	13
25	Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. <i>Cancer Gene Therapy</i> , 2021, 28, 1325-1338.	4.6	13
26	A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11509-11509.	1.6	13
27	Extraskeletal Myxoid Chondrosarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 744-748.	1.3	11
28	Successful treatment of lipofibromatosis-like neural tumor of the lumbar spine with an NTRK-fusion inhibitor. <i>Clinical Sarcoma Research</i> , 2020, 10, 14.	2.3	11
29	Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. <i>British Journal of Cancer</i> , 2020, 122, 812-822.	6.4	11
30	Young Adult Populations Face Yet Another Barrier to Care With Insurers: Limited Access to Proton Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1496-1504.	0.8	11
31	Evaluating the Soft Tissue Sarcoma Paradigm for the Local Management of Extraskeletal Ewing Sarcoma. <i>Oncologist</i> , 2021, 26, 250-260.	3.7	9
32	Impact of Lagtime, Health Insurance Type, and Income Status at Diagnosis on the Long-Term Survival of Adolescent and Young Adult Cancer Patients. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, 10, 164-174.	1.3	8
33	Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. <i>Cancer Medicine</i> , 2022, 11, 3471-3478.	2.8	7
34	Extraskeletal Osteosarcomas. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 238-242.	1.3	6
35	Pilot study of NKTR214 and nivolumab in patients with sarcomas.. <i>Journal of Clinical Oncology</i> , 2019, 37, 11010-11010.	1.6	6
36	Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1176-1184.	2.5	6

#	ARTICLE	IF	CITATIONS
37	Emergency Department Visits by Adolescent and Young Adult Cancer Patients Compared with Pediatric Cancer Patients in the United States. <i>Journal of Adolescent and Young Adult Oncology</i> , 2018, 7, 553-564.	1.3	5
38	Disparities in the long-term survival of adolescent and young adult diffuse large B cell lymphoma survivors. <i>Cancer Epidemiology</i> , 2021, 75, 102044.	1.9	5
39	Short-Term Changes in Cardiac Function in Osteosarcoma Patients Receiving Anthracyclines. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 385-386.	1.3	4
40	Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS11575-TPS11575.	1.6	4
41	Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma. <i>Cancers</i> , 2021, 13, 5249.	3.7	4
42	Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions. <i>Advances in Radiation Oncology</i> , 2022, 7, 100913.	1.2	4
43	Improving Outcomes for Adolescents and Young Adults With Sarcoma: A Focus on Cancer Care Delivery. <i>Journal of Oncology Practice</i> , 2019, 15, 253-254.	2.5	3
44	Improved Survival of Young Adults with Cancer Following the Passage of the Affordable Care Act. <i>Oncologist</i> , 2022, 27, 135-143.	3.7	3
45	Factors impacting adolescent and young adult cancer patients's decision to pursue genetic counseling and testing. <i>Supportive Care in Cancer</i> , 2022, 30, 5481-5489.	2.2	2
46	A phase I trial of aerosol gemcitabine for the treatment of patients with solid tumors and lung metastases.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS3645-TPS3645.	1.6	1
47	Parallel genomic and immune profiling of relapsed and metastatic osteosarcoma to reveal bases of low immunogenicity.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10520-10520.	1.6	0
48	Genome and transcriptome profiling of relapsed and metastatic osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11522-11522.	1.6	0